KRON
Price:
$1.07
Market Cap:
$64.56M
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 ...[Read more]
Industry
Biotechnology
IPO Date
2020-10-09
Stock Exchange
NASDAQ
Ticker
KRON
According to Kronos Bio, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 15.40M. This represents a change of -54.57% compared to the average of 33.89M of the last 4 quarters.
The mean historical Enterprise Value of Kronos Bio, Inc. over the last ten years is 645.07M. The current 15.40M Enterprise Value has changed 138.71% with respect to the historical average. Over the past ten years (40 quarters), KRON's Enterprise Value was at its highest in in the September 2020 quarter at 1.52B. The Enterprise Value was at its lowest in in the September 2022 quarter at -49908787.15.
Average
645.07M
Median
599.55M
Minimum
36.13M
Maximum
1.40B
Discovering the peaks and valleys of Kronos Bio, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 84.54%
Maximum Annual Enterprise Value = 1.40B
Minimum Annual Increase = -89.47%
Minimum Annual Enterprise Value = 36.13M
Year | Enterprise Value | Change |
---|---|---|
2023 | 36.13M | -21.74% |
2022 | 46.16M | -89.47% |
2021 | 438.35M | -63.01% |
2020 | 1.19B | -15.58% |
2019 | 1.40B | 84.54% |
The current Enterprise Value of Kronos Bio, Inc. (KRON) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
173.55M
5-year avg
621.94M
10-year avg
645.07M
Kronos Bio, Inc.’s Enterprise Value is greater than Cyclerion Therapeutics, Inc. (8.10M), less than Larimar Therapeutics, Inc. (401.63M), greater than Addex Therapeutics Ltd (7.42M), greater than Achilles Therapeutics plc (-39276958.00), greater than NextCure, Inc. (10.17M), less than CytomX Therapeutics, Inc. (68.63M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Spero Therapeutics, Inc. (-9517252.00), less than Assembly Biosciences, Inc. (79.11M), less than Replimune Group, Inc. (914.93M), less than Nuvectis Pharma, Inc. (75.76M), less than Lyra Therapeutics, Inc. (25.33M), less than Gossamer Bio, Inc. (348.85M), less than Crinetics Pharmaceuticals, Inc. (4.99B), less than Inhibrx Biosciences, Inc. (21.56M), less than Merus N.V. (2.56B), less than Lyell Immunopharma, Inc. (214.09M), less than Generation Bio Co. (156.95M), less than Erasca, Inc. (826.58M), less than C4 Therapeutics, Inc. (303.21M), less than Edgewise Therapeutics, Inc. (2.82B),
Company | Enterprise Value | Market cap |
---|---|---|
8.10M | $10.98M | |
401.63M | $431.33M | |
7.42M | $11.71M | |
-39276958.00 | $43.16M | |
10.17M | $32.49M | |
68.63M | $98.61M | |
-6333315.00 | $8.20M | |
-9517252.00 | $62.15M | |
79.11M | $106.12M | |
914.93M | $952.30M | |
75.76M | $92.93M | |
25.33M | $13.81M | |
348.85M | $173.69M | |
4.99B | $5.25B | |
21.56M | $216.05M | |
2.56B | $2.99B | |
214.09M | $262.95M | |
156.95M | $84.83M | |
826.58M | $842.53M | |
303.21M | $295.77M | |
2.82B | $2.86B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kronos Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kronos Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Kronos Bio, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Kronos Bio, Inc. (KRON)?
What is the 3-year average Enterprise Value for Kronos Bio, Inc. (KRON)?
What is the 5-year average Enterprise Value for Kronos Bio, Inc. (KRON)?
How does the current Enterprise Value for Kronos Bio, Inc. (KRON) compare to its historical average?